Journal ArticleDOI
Bone and cancer: Pathophysiology and treatment of metastases
Reads0
Chats0
TLDR
There are now several studies which have examined the effects of the bisphosphonates on skeletal morbidity in breast cancer, and both clodronate and pamidronate decrease the incidence of hypercalcemia, bone pain, and pathological fractures, but do not significantly alter mortality.About:
This article is published in Bone.The article was published on 1995-08-01. It has received 84 citations till now. The article focuses on the topics: Bone disease & Bone remodeling.read more
Citations
More filters
Journal ArticleDOI
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis
Young-Yun Kong,Hiroki Yoshida,Ildiko Sarosi,Hong-Lin Tan,Emma Timms,Casey Capparelli,Sean Morony,Antonio J. Oliveira-dos-Santos,Gwyneth Van,Annick Itie,Wilson Khoo,Andrew Wakeham,Colin R. Dunstan,David L. Lacey,Tak W. Mak,William J. Boyle,Josef M. Penninger +16 more
TL;DR: OPGL is a new regulator of lymph-node organogenesis and lymphocyte development and is an essential osteoclast differentiation factor in vivo.
Journal ArticleDOI
Reduction in New Metastases in Breast Cancer with Adjuvant Clodronate Treatment
Ingo J. Diel,Erich-Franz Solomayer,SD Costa,Christina Gollan,R. Goerner,Diethelm Wallwiener,Manfred Kaufmann,Gunther Bastert +7 more
TL;DR: Clodronate can reduce the incidence and number of new bony and visceral metastases in women with breast cancer who are at high risk for distant metastases.
Journal ArticleDOI
A systematic review of the role of bisphosphonates in metastatic disease.
TL;DR: Most evidence supports the use of intravenous aminobisphosphonates in breast cancer patients where fractures are prevented, and economic modelling showed that for acute hypercalcaemia, drugs with the longest cumulative duration of normocalcaemia were most cost-effective.
Journal ArticleDOI
Cancer and bone
TL;DR: Local Mechanisms by Which Tumors Affect the Skeleton A. Clinical manifestations B. Pathophysiology of the metastatic process to bone C. Local tumor syndromes in bone D. Therapy of tumor in bone
Reference EntryDOI
Bisphosphonates for breast cancer
Nick Pavlakis,Martin R. Stockler +1 more
TL;DR: This systematic review found that bisphosphonates reduced the risk of developing a skeletal event by 14% in women with advanced breast cancer and existing bone metastases, and statistically significant reductions were reported in six trials.
References
More filters
Journal ArticleDOI
Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease.
TL;DR: By inhibiting bone resorption, these compounds correct hypercalcaemia and hypercalciuria, reduce pain, the occurrence of fractures, as well as the development of new osteolytic lesions, and in consequence improve the quality of life.
Journal ArticleDOI
Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer.
Alexander H.G. Paterson,Trevor J. Powles,John A. Kanis,Eugene V. McCloskey,J. Hanson,Stanley W. Ashley +5 more
TL;DR: Findings indicate that oral clodronate has a beneficial effect on the skeletal morbidity associated with breast cancer and should be considered as antiosteolytic therapy in affected patients.
Book
Pathophysiology and Treatment of Paget's Disease of Bone
TL;DR: Topics covered in this book include epidemiology, pathophysiology, imaging techniques, biochemical and endocrine aspects, clinical features and complications, differential diagnosis, drug treatments, management and assessment of response and aetiology.
Journal ArticleDOI
Interleukin‐1β is a potent inhibitor of bone formation in vitro
TL;DR: Inhibition of bone formation occurred when cultures were exposed to IL‐1β at both early and late time periods and was unaffected by the presence of indomethacin or by the osteoclast inhibitors calcitonin and γ‐interferon.
Journal ArticleDOI
Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases.
Inkeri Elomaa,Carl Blomqvist,P. Gröhn,L. Porkka,A.-L. Kairento,K. Selander,Christel Lamberg-Allardt,Holmström T +7 more
TL;DR: The formation of new bone metastases and the growth of old ones seemed to be retarded by Cl2MDP, which seemed to reduce bone pain and bone resorption and prevent the development of hypercalcaemia caused by osteolytic metastases.